Related Experiment Video

Updated: Jun 13, 2026

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

Circulating tumor cells in cancer therapy: are we off target?

C Raimondi1, G Naso, A Gradilone

  • 1Division of Medical Oncology, Sapienza University of Rome, Rome, Italy. cristina.raimondi@libero.it

Current Cancer Drug Targets
|April 14, 2010
PubMed

Insights

Metastatic process causes most cancer deaths. Targeting drug-resistant circulating tumor cells (CTCs) may individualize cancer therapy by addressing treatment failure at distant sites.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Metastasis is the primary cause of cancer-related mortality.
  • Metastatic disease arises from a selective process involving a minority of tumor cells surviving in circulation.
  • These circulating tumor cells (CTCs) are implicated in treatment failure due to drug resistance.

Purpose of the Study:

  • To investigate the role of circulating tumor cells (CTCs) in cancer metastasis and treatment failure.
  • To explore the potential of targeting CTCs as a novel therapeutic strategy.
  • To evaluate whether current cancer therapies, focused on primary tumors, are overlooking a critical factor in patient outcomes.

Main Methods:

  • Analysis of existing clinical and scientific literature on the metastatic process.
  • Review of data concerning the characteristics and implications of circulating tumor cells (CTCs).
  • Evaluation of current pharmacological approaches in cancer treatment.

Main Results:

  • Circulating tumor cells (CTCs) are a small subpopulation of tumor cells capable of survival and growth at distant sites.
  • CTCs are widely accepted as being drug-resistant, contributing significantly to treatment failure.
  • Current cancer therapies primarily target the primary tumor, potentially neglecting the impact of CTCs.

Conclusions:

  • Targeting circulating tumor cells (CTCs) presents a promising new avenue for individualized anticancer therapy.
  • Addressing CTCs may overcome treatment resistance and improve outcomes for patients with metastatic disease.
  • A shift in therapeutic strategy towards targeting CTCs could represent a more effective approach to managing cancer spread.

More Related Videos

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...